Evolus, Inc.
EOLSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeEvolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. The company carries a $463.0M market cap, placing it firmly in the small-cap category. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Market Cap
$463.0M
Beta
1.34
P/E (TTM)
—
P/E (Fwd)
23.97
EPS (TTM)
$-0.53
EPS (Fwd)
$0.29
ROE
—
ROA
-5.7%
Cash
$45.2M
Total Debt
$164.8M
Free CF
-$1.8M
52W Change
-2.9%
Annual Financials
Cash vs Debt
Where EOLS stands vs its 150-day and 200-day moving averages
As of the September 28, 2026 close, EOLS finished 26.11% above its 150-day moving average ($6.32) and 29.80% above its 200-day moving average ($6.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EOLS overbought or oversold?
At the September 28, 2026 close, EOLS's RSI(14) was 25.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Evolus, Inc. carries $164.8M in total debt against $45.2M in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$1.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $148.6M (2022) to $297.2M (2025), reflecting a 100% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Evolus, Inc.'s trajectory.